Albacete

• TRAP study: Testosterone for Androgen Receptor Polymorphism. Not authorised
  2024-510596-37-00 6 low ovarian reserve according to Bologna criteria and carriers of andr
• TRAP study: Testosterone for Androgen Receptor Polymorphism. Pending
  2024-510596-37-01 5 low ovarian reserve according to Bologna criteria and carriers of andr
• CLINICAL TRIAL WITH APROTININ IN THE ACUTE RESPIRATORY DISTRESS SYNDROME TREATMENT Pending
  2025-520826-39-00 5 ACUTE RESPIRATORY DISTRESS SYNDROME
• A clinical trial to evaluate the efficacy and safety of a mixture of allergenic extracts of D. pteronyssinus and D. farinae, in patients suf … Pending
  2025-521230-29-00 5 Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Der
• Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES) Pending
  2025-521709-42-00 5 Allergic rhinoconjunctivitis with or without asthma due to clinically
• Grass Immunotherapy for Rhinitis and Asthma (GIRA) Pending
  2025-521736-10-00 5 Allergic rhinoconjunctivitis with or without controlled asthma
• Dose determination study of Phleum pratense allergenic extract for immunotherapy treatment, administered via sublingual route, standardized … Pending
  2025-522730-31-00 4 Allergic rhinitis/rhinoconjunctivitis caused by grass polen allergy
• A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia … Pending
  2025-523238-17-00 4 Acute myeloid leukemia
• A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Pa … Pending
  2025-524308-31-00 4 Acute myeloid leukemia
• VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA) Recruiting
  2024-512436-29-00 11 2026-03-27 CARDIOVASCULAR DISEASES
• Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g … Recruiting
  2025-521314-25-00 5 2026-03-19 NPM1-m and KMT2A-r Acute Myeloid Leukemia
• A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting
  2024-513911-28-00 10 2026-03-04 Acute Ischemic Stroke
• Assess the safety and efficacy of sovateltide in patients with acute cerebral ischemic stroke. Recruiting
  2024-519551-29-00 5 2025-08-21 Acute cerebral ischemic stroke
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting
  2023-507936-20-00 5 2025-05-05 Acute myeloid leukemia
• IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA Recruiting
  2024-514517-35-00 5 2025-02-27 Acute myeloid leukemia
• A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn … Recruiting
  2022-501709-11-00 5 2023-06-06 Isocitrate deshydrogenase1 mutation-positive (IDH1m) acute myeloid leu
• LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting
  2023-506784-33-00 5 2021-01-19 RET fusion-Positive NSCLC
• A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s … Recruiting
  2025-522979-29-00 5 2026-04-30 Acute myeloid leukemia
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• A Randomized, Open-labelled, Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard … Recruiting
  2025-521634-29-00 5 2026-03-02 Acute Myeloid Leukemia
• EFFICACY OF FARICIMAB IN PATIENTS WITH SUBRETINAL HYPER-REFLECTIVE MATERIAL Recruiting
  2025-522701-38-00 6 2026-02-26 SUBRETINAL HYPERREFLECTIVE MATERIAL
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has … Recruiting
  2025-521636-10-00 4 2026-02-04 Progressive Forms of Multiple Sclerosis (PMS)
• A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Recruiting
  2024-517980-22-00 4 2025-12-10 Multiple Sclerosis (MS)
• Phase II study of tarlatamab as a follow-up treatment after chemo and radiation in patients with small cell lung cancer (SCLC) who cannot re … Recruiting
  2024-515201-26-00 4 2025-12-09 Small cell lung cancer (SCLC)

Showing 1–24 of 58 trials